M. Puttini

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

C. Gambacorti-Passerini, E. Sala, L. Mologni, 2007, Anti-cancer agents in medicinal chemistry.

Characterization of compound 584, an Abl kinase inhibitor with lasting effects

M. Kubbutat, L. Scapozza, A. Zambon, 2008, Haematologica.

NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

A. Villa, D. Perrotti, S. Redaelli, 2007, Blood.

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

L. Scapozza, F. Formelli, S. Redaelli, 2006, Cancer research.

Inhibition of RET tyrosine kinase by SU5416.

L. Scapozza, J. Bain, F. Formelli, 2006, Journal of molecular endocrinology.

Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

A. Nagler, M. Deininger, M. Valsecchi, 2011, Journal of the National Cancer Institute.

Effect of imatinib on haematopoietic recovery following idarubicin exposure

S. Pilotti, F. Formelli, C. Gambacorti-Passerini, 2003, Leukemia.